Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Department Of Defense was posted on May 1, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Organoid Cytomorphic Intelligence Resulting from Convergent Understanding and Information Transfer (O-Circuit)

Closed
DARPA-PS-26-28Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.
National Institutes Of Health

POSTED

about 22 hours ago

DEADLINE

in over 2 years
NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The O-Circuit program, solicited by DARPA under solicitation number DARPA-PS-26-28, aims to develop an integrated biological processing unit (BPU) leveraging neural tissue systems to overcome power inefficiencies inherent in semiconductor-based computation, particularly for edge applications in austere Department of War environments. The program seeks to enhance the learning, inference, and computational memory capacities of synthetic biological intelligence systems to support advanced AI/ML workloads with reduced energy consumption. This 32-month Other Transaction Agreement (OTA) prototype effort includes milestone-based deliveries that require demonstrable technical progress verified via government-led inspection at designated test and evaluation sites on the West Coast. Key deliverables encompass prototype hardware, milestone reports, final technical and executive summaries, and property reports, all submitted through DARPA’s VAULT system and fully compliant with Controlled Unclassified Information (CUI) marking and safeguarding standards per NIST SP 800-171. As a research and development initiative funded under 10 U.S.C. § 4022, the agreement employs a trade-off award process emphasizing problem comprehension, execution capability, and budget alignment rather than lowest-price criteria. The contract mandates comprehensive organizational conflict of interest disclosures, rigorous security and export control compliance, and prior government approval before any public information release. Proposers must submit encrypted, unclassified abstracts by May 20, 2026, to a designated DARPA email, following specific format and content guidelines that include a technical understanding, approach, capability, and budget estimate. Administrative requirements include registration in SAM with UEI and CAGE codes, certifications related to socioeconomic status, and adherence to continuous reporting on lobbying, tax liabilities, and use of covered telecommunications equipment. Payments are milestone-tied and processed through DFAS via the Wide Area Workflow (WAWF) system, with invoicing and acceptance tightly controlled by government representatives. The contract’s scope extends to potential future follow-on production awards, while all work remains conditional on government collaboration, successful milestone validation, and further regulatory reviews.

General Info

Develop integrated neural biological processors for energy-efficient AI in austere defense environments.

Agency

Department Of Defense → Defense Advanced Research Projects Agcy

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

VA

Set-Aside

NONE

Documents

(4)

DARPA-PS-26-28-Attachment_A-Summary_Slide_Template_final.pptx

PPTX

DARPA-PS-26-28 O-Circuit Abstract Template

DOCXabstract-template

DARPA Other Transaction Prototype Agreement Sample Fixed Support Nontraditional

DOCXcontract-document

DARPA-PS-26-28 Organoid Cytomorphic Intelligence Program Solicitation

PDFrfp

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Advanced Research Projects Agcy
Contacts1 person available
OfficeARLINGTON, VA, 222032114, USA
Organization / Agency
Department Of Defense → Defense Advanced Research Projects Agcy
Office AddressARLINGTON, VA, 222032114, USA
Contacts
Dr. Jeffrey Zaleski Program Manager DARPA/BTO

Full Description

Show more
While semiconductor-based computation is readily deployed in well-resourced environments, it is challenged by sustained applications ‘at the edge’ due to inherent power inefficiencies. This is a particular limitation for the Department of War (DoW) when operating in austere environments, especially when using advanced artificial intelligence and machine learning (AI/ML) applications with high energy demands for both training and inference. New unconventional computing concepts, such as synthetic biological intelligence, have the potential to fundamentally address these limitations but do not yet possess the necessary training and inference capabilities for practical applications. To meet these needs, the O-Circuit program will explore methods for improving the learning, inference, and computational memory of neural tissue systems to develop an integrated biological processing unit (BPU) that establishes a new paradigm for sense-compute-act for edge applications.